{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:05:27Z","timestamp":1772136327002,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan","award":["TCMF-A 106-01-09"],"award-info":[{"award-number":["TCMF-A 106-01-09"]}]},{"name":"Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan","award":["TCMF-A 106-01-09"],"award-info":[{"award-number":["TCMF-A 106-01-09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This study aimed to investigate the relationship of four chronic kidney disease\u2013mineral and bone disorder (CKD\u2013MBD) biomarkers, including intact parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), soluble klotho, and fetuin-A, with aortic stiffness in peritoneal dialysis (PD) patients, comparing those with and without diabetes mellitus (DM). A total of 213 patients (mean age 58\u2009\u00b1\u200914\u00a0years; 81 (38.0%) patients with DM) were enrolled. Their aortic pulse wave velocity (PWV) was measured using pressure applanation tonometry, while serum intact PTH, FGF23, \u03b1-klotho, and fetuin-A levels were measured using enzyme-linked immunosorbent assay. Overall, patients with DM had higher aortic PWV than those without (9.9\u2009\u00b1\u20091.8 vs. 8.6\u2009\u00b1\u20091.4\u00a0m\/s,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Among the four CKD\u2013MBD biomarkers, FGF23 levels were significantly lower in DM group (462 [127\u20131790] vs. 1237 [251\u20133120] pg\/mL,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.028) and log-FGF23 independently predicted aortic PWV in DM group (\u03b2: 0.61, 95% confidence interval: 0.06\u20131.16,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.029 in DM group; \u03b2: 0.10, 95% confidence interval: \u2212\u20090.24\u20130.45,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.546 in nonDM group; interaction\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016). In conclusion, the association between FGF23 and aortic PWV was significantly modified by DM status in PD patients.\n                  <\/jats:p>","DOI":"10.1038\/s41598-024-55364-3","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T11:02:33Z","timestamp":1708772553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diabetes mellitus modifies the association between chronic kidney disease\u2013mineral and bone disorder biomarkers and aortic stiffness in peritoneal dialysis patients"],"prefix":"10.1038","volume":"14","author":[{"given":"Hsiang-Jung","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bang-Gee","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Pi","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szu-Chun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"55364_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","volume":"382","author":"RT Gansevoort","year":"2013","unstructured":"Gansevoort, R. T. et al. Chronic kidney disease and cardiovascular risk: Epidemiology, mechanisms, and prevention. Lancet 382, 339\u2013352. https:\/\/doi.org\/10.1016\/S0140-6736(13)60595-4 (2013).","journal-title":"Lancet"},{"key":"55364_CR2","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1681\/ASN.V92267","volume":"9","author":"RN Foley","year":"1998","unstructured":"Foley, R. N., Parfrey, P. S. & Sarnak, M. J. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 9, S16-23 (1998).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55364_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1111\/j.1523-1755.2004.00657.x","volume":"65","author":"AK Cheung","year":"2004","unstructured":"Cheung, A. K. et al. Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO study. Kidney Int. 65, 2380\u20132389. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00657.x (2004).","journal-title":"Kidney Int."},{"key":"55364_CR4","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/01.asn.0000113243.24155.2f","volume":"15","author":"LA Stevens","year":"2004","unstructured":"Stevens, L. A., Djurdjev, O., Cardew, S., Cameron, E. C. & Levin, A. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 15, 770\u2013779. https:\/\/doi.org\/10.1097\/01.asn.0000113243.24155.2f (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55364_CR5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.bone.2016.11.012","volume":"100","author":"S Yamada","year":"2017","unstructured":"Yamada, S. & Giachelli, C. M. Vascular calcification in CKD\u2013MBD: Roles for phosphate, FGF23, and Klotho. Bone 100, 87\u201393. https:\/\/doi.org\/10.1016\/j.bone.2016.11.012 (2017).","journal-title":"Bone"},{"key":"55364_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.bone.2017.01.023","volume":"100","author":"KA Hruska","year":"2017","unstructured":"Hruska, K. A., Sugatani, T., Agapova, O. & Fang, Y. The chronic kidney disease\u2013mineral bone disorder (CKD\u2013MBD): Advances in pathophysiology. Bone 100, 80\u201386. https:\/\/doi.org\/10.1016\/j.bone.2017.01.023 (2017).","journal-title":"Bone"},{"key":"55364_CR7","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/ndt\/gfs460","volume":"28","author":"I Pavik","year":"2013","unstructured":"Pavik, I. et al. Secreted Klotho and FGF23 in chronic kidney disease stage 1 to 5: A sequence suggested from a cross-sectional study. Nephrol. Dial. Transplant. 28, 352\u2013359. https:\/\/doi.org\/10.1093\/ndt\/gfs460 (2013).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR8","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370\u20131378. https:\/\/doi.org\/10.1038\/ki.2011.47 (2011).","journal-title":"Kidney Int."},{"key":"55364_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/ki.2012.176","volume":"82","author":"M Wolf","year":"2012","unstructured":"Wolf, M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 82, 737\u2013747. https:\/\/doi.org\/10.1038\/ki.2012.176 (2012).","journal-title":"Kidney Int."},{"key":"55364_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1525-139x.2007.00308.x","volume":"20","author":"J Stubbs","year":"2007","unstructured":"Stubbs, J., Liu, S. & Quarles, L. D. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin. Dial. 20, 302\u2013308. https:\/\/doi.org\/10.1111\/j.1525-139x.2007.00308.x (2007).","journal-title":"Semin. Dial."},{"key":"55364_CR11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/ki.2008.643","volume":"75","author":"D Pri\u00e9","year":"2009","unstructured":"Pri\u00e9, D., Torres, P. U. & Friedlander, G. Latest findings in phosphate homeostasis. Kidney Int. 75, 882\u2013889. https:\/\/doi.org\/10.1038\/ki.2008.643 (2009).","journal-title":"Kidney Int."},{"key":"55364_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/kisup.2011.29","volume":"1","author":"MG Vervloet","year":"2011","unstructured":"Vervloet, M. G. & Larsson, T. E. Fibroblast growth factor-23 and Klotho in chronic kidney disease. Kidney Int. Suppl. 1, 130\u2013135. https:\/\/doi.org\/10.1038\/kisup.2011.29 (2011).","journal-title":"Kidney Int. Suppl."},{"key":"55364_CR13","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2215\/cjn.02680310","volume":"5","author":"D Pri\u00e9","year":"2010","unstructured":"Pri\u00e9, D. & Friedlander, G. Reciprocal control of 1,25-dihydroxyvitamin D and FGF23 formation involving the FGF23\/Klotho system. Clin. J. Am. Soc. Nephrol. 5, 1717\u20131722. https:\/\/doi.org\/10.2215\/cjn.02680310 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"55364_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3906\/sag-1809-43","volume":"49","author":"R Mutluay","year":"2019","unstructured":"Mutluay, R. et al. Serum fetuin-A is associated with the components of MIAC (malnutrition, inflammation, atherosclerosis, calcification) syndrome in different stages of chronic kidney disease. Turk. J. Med. Sci. 49, 327\u2013335. https:\/\/doi.org\/10.3906\/sag-1809-43 (2019).","journal-title":"Turk. J. Med. Sci."},{"key":"55364_CR15","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1080\/0886022x.2021.1969248","volume":"43","author":"C Sevinc","year":"2021","unstructured":"Sevinc, C., Yilmaz, G. & Ustundag, S. The relationship between calcification inhibitor levels in chronic kidney disease and the development of atherosclerosis. Ren. Fail. 43, 1349\u20131358. https:\/\/doi.org\/10.1080\/0886022x.2021.1969248 (2021).","journal-title":"Ren. Fail."},{"key":"55364_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s11892-020-01335-7","volume":"20","author":"SMH Yeung","year":"2020","unstructured":"Yeung, S. M. H., Bakker, S. J. L., Laverman, G. D. & De Borst, M. H. Fibroblast growth factor 23 and adverse clinical outcomes in type 2 diabetes: A bitter-sweet symphony. Curr. Diabetes Rep. 20, 50. https:\/\/doi.org\/10.1007\/s11892-020-01335-7 (2020).","journal-title":"Curr. Diabetes Rep."},{"key":"55364_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.2337\/dc11-2235","volume":"35","author":"P Wahl","year":"2012","unstructured":"Wahl, P. et al. Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease. Diabetes Care 35, 994\u20131001. https:\/\/doi.org\/10.2337\/dc11-2235 (2012).","journal-title":"Diabetes Care"},{"key":"55364_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/ajh\/hpac010","volume":"35","author":"C Esposito","year":"2022","unstructured":"Esposito, C. et al. Comparing central aortic pressures obtained using a SphygmoCor device to pressures obtained using a pressure catheter. Am. J. Hypertens. 35, 397\u2013406. https:\/\/doi.org\/10.1093\/ajh\/hpac010 (2022).","journal-title":"Am. J. Hypertens."},{"key":"55364_CR19","doi-asserted-by":"publisher","first-page":"M139","DOI":"10.1097\/00002480-199207000-00004","volume":"38","author":"KD Nolph","year":"1992","unstructured":"Nolph, K. D. et al. Cross-sectional assessment of weekly urea and creatinine clearances in patients on continuous ambulatory peritoneal dialysis. ASAIO J. (Am. Soc. Artif. Intern. Organs 1992) 38, M139\u2013M142. https:\/\/doi.org\/10.1097\/00002480-199207000-00004 (1992).","journal-title":"ASAIO J. (Am. Soc. Artif. Intern. Organs 1992)"},{"key":"55364_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/ki.2013.332","volume":"85","author":"R Jimbo","year":"2014","unstructured":"Jimbo, R. et al. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney Int. 85, 1103\u20131111. https:\/\/doi.org\/10.1038\/ki.2013.332 (2014).","journal-title":"Kidney Int."},{"key":"55364_CR21","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1681\/asn.2010121251","volume":"22","author":"MH de Borst","year":"2011","unstructured":"de Borst, M. H., Vervloet, M. G., ter Wee, P. M. & Navis, G. Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-Klotho in chronic kidney disease. J. Am. Soc. Nephrol. 22, 1603\u20131609. https:\/\/doi.org\/10.1681\/asn.2010121251 (2011).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55364_CR22","doi-asserted-by":"publisher","first-page":"E426","DOI":"10.1152\/ajpendo.00264.2014","volume":"307","author":"N Silswal","year":"2014","unstructured":"Silswal, N. et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am. J. Physiol. Endocrinol. Metab. 307, E426\u2013E436. https:\/\/doi.org\/10.1152\/ajpendo.00264.2014 (2014).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"55364_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1093\/ndt\/gfac220","volume":"38","author":"N Vergara","year":"2022","unstructured":"Vergara, N. et al. The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function. Nephrol. Dial. Transplant. 38, 322\u2013343. https:\/\/doi.org\/10.1093\/ndt\/gfac220 (2022).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.kint.2018.02.026","volume":"94","author":"K Durlacher-Betzer","year":"2018","unstructured":"Durlacher-Betzer, K. et al. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 94, 315\u2013325. https:\/\/doi.org\/10.1016\/j.kint.2018.02.026 (2018).","journal-title":"Kidney Int."},{"key":"55364_CR25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.kint.2019.04.009","volume":"96","author":"D Egli-Spichtig","year":"2019","unstructured":"Egli-Spichtig, D. et al. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney Int. 96, 890\u2013905. https:\/\/doi.org\/10.1016\/j.kint.2019.04.009 (2019).","journal-title":"Kidney Int."},{"key":"55364_CR26","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.atherosclerosis.2009.01.001","volume":"205","author":"MAI Mirza","year":"2009","unstructured":"Mirza, M. A. I., Larsson, A., Lind, L. & Larsson, T. E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis 205, 385\u2013390. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2009.01.001 (2009).","journal-title":"Atherosclerosis"},{"key":"55364_CR27","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1093\/ndt\/gfp205","volume":"24","author":"MAI Mirza","year":"2009","unstructured":"Mirza, M. A. I. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol. Dial. Transplant. 24, 3125\u20133131. https:\/\/doi.org\/10.1093\/ndt\/gfp205 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR28","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1093\/ndt\/gfq089","volume":"25","author":"MM Nasrallah","year":"2010","unstructured":"Nasrallah, M. M. et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol. Dial. Transplant. 25, 2679\u20132685. https:\/\/doi.org\/10.1093\/ndt\/gfq089 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR29","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2215\/CJN.02160212","volume":"7","author":"AM Khan","year":"2012","unstructured":"Khan, A. M., Chirinos, J. A., Litt, H., Yang, W. & Rosas, S. E. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin. J. Am. Soc. Nephrol. CJASN 7, 2017\u20132022. https:\/\/doi.org\/10.2215\/CJN.02160212 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"55364_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/1471-2369-14-241","volume":"14","author":"A Ozkok","year":"2013","unstructured":"Ozkok, A. et al. FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol. 14, 241. https:\/\/doi.org\/10.1186\/1471-2369-14-241 (2013).","journal-title":"BMC Nephrol."},{"key":"55364_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000355859","volume":"124","author":"E Asicioglu","year":"2013","unstructured":"Asicioglu, E. et al. Fibroblast growth factor-23 levels are associated with vascular calcifications in peritoneal dialysis patients. Nephron Clin. Pract. 124, 89\u201393. https:\/\/doi.org\/10.1159\/000355859 (2013).","journal-title":"Nephron Clin. Pract."},{"key":"55364_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.4238\/2015.January.30.15","volume":"14","author":"Y Zeng","year":"2015","unstructured":"Zeng, Y. et al. Role of fibroblast growth factor-23 in the pathogenesis of atherosclerosis in peritoneal dialysis patients. Genet. Mol. Res. GMR 14, 719\u2013729. https:\/\/doi.org\/10.4238\/2015.January.30.15 (2015).","journal-title":"Genet. Mol. Res. GMR"},{"key":"55364_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140222","volume":"10","author":"G Llaurad\u00f3","year":"2015","unstructured":"Llaurad\u00f3, G. et al. FGF-23\/vitamin D axis in type 1 diabetes: The potential role of mineral metabolism in arterial stiffness. PLoS One 10, e0140222. https:\/\/doi.org\/10.1371\/journal.pone.0140222 (2015).","journal-title":"PLoS One"},{"key":"55364_CR34","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/dmrr.2787","volume":"32","author":"J Tu\u00f1\u00f3n","year":"2016","unstructured":"Tu\u00f1\u00f3n, J. et al. Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease. Diabetes\/Metab. Res. Rev. 32, 685\u2013693. https:\/\/doi.org\/10.1002\/dmrr.2787 (2016).","journal-title":"Diabetes\/Metab. Res. Rev."},{"key":"55364_CR35","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/j.ekir.2020.07.033","volume":"5","author":"J Fitzpatrick","year":"2020","unstructured":"Fitzpatrick, J. et al. Calcification biomarkers, subclinical vascular disease, and mortality among multiethnic dialysis patients. Kidney Int. Rep. 5, 1729\u20131737. https:\/\/doi.org\/10.1016\/j.ekir.2020.07.033 (2020).","journal-title":"Kidney Int. Rep."},{"key":"55364_CR36","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1681\/asn.2017070772","volume":"29","author":"T Isakova","year":"2018","unstructured":"Isakova, T. et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J. Am. Soc. Nephrol. 29, 579\u2013590. https:\/\/doi.org\/10.1681\/asn.2017070772 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55364_CR37","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.ekir.2020.08.013","volume":"5","author":"H Komaba","year":"2020","unstructured":"Komaba, H. et al. Fibroblast growth factor 23 and mortality among prevalent hemodialysis patients in the japan dialysis outcomes and practice patterns study. Kidney Int. Rep. 5, 1956\u20131964. https:\/\/doi.org\/10.1016\/j.ekir.2020.08.013 (2020).","journal-title":"Kidney Int. Rep."},{"key":"55364_CR38","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1681\/asn.2014101009","volume":"27","author":"M Chonchol","year":"2016","unstructured":"Chonchol, M., Greene, T., Zhang, Y., Hoofnagle, A. N. & Cheung, A. K. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J. Am. Soc. Nephrol. 27, 227\u2013237. https:\/\/doi.org\/10.1681\/asn.2014101009 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"55364_CR39","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.2215\/CJN.04290511","volume":"6","author":"T Isakova","year":"2011","unstructured":"Isakova, T. et al. Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin. J. Am. Soc. Nephrol. CJASN 6, 2688\u20132695. https:\/\/doi.org\/10.2215\/CJN.04290511 (2011).","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"55364_CR40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/1744-9987.12170","volume":"18","author":"S Yamada","year":"2014","unstructured":"Yamada, S. et al. Relationship between residual renal function and serum fibroblast growth factor 23 in patients on peritoneal dialysis. Ther. Apheresis Dial. Off. Peer Rev. J. Int. Soc. Apheresis Jpn. Soc. Apheresis Jpn. Soc. Dial. Ther. 18, 383\u2013390. https:\/\/doi.org\/10.1111\/1744-9987.12170 (2014).","journal-title":"Ther. Apheresis Dial. Off. Peer Rev. J. Int. Soc. Apheresis Jpn. Soc. Apheresis Jpn. Soc. Dial. Ther."},{"key":"55364_CR41","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.1073\/pnas.1800160115","volume":"115","author":"L B\u00e4r","year":"2018","unstructured":"B\u00e4r, L. et al. Insulin suppresses the production of fibroblast growth factor 23 (FGF23). Proc. Natl. Acad. Sci. U. S. A. 115, 5804\u20135809. https:\/\/doi.org\/10.1073\/pnas.1800160115 (2018).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"55364_CR42","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1093\/ndt\/gfk045","volume":"21","author":"MM Hermans","year":"2006","unstructured":"Hermans, M. M. et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol. Dial. Transplant. 21, 1293\u20131299. https:\/\/doi.org\/10.1093\/ndt\/gfk045 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR43","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1093\/ndt\/gfl409","volume":"21","author":"T Stomp\u00f3r","year":"2006","unstructured":"Stomp\u00f3r, T. et al. Pulse wave velocity and proteins regulating vascular calcification and bone mineralization in patients treated with peritoneal dialysis. Nephrol. Dial. Transplant. 21, 3605\u20133606. https:\/\/doi.org\/10.1093\/ndt\/gfl409 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR44","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1172\/jci17202","volume":"112","author":"C Schafer","year":"2003","unstructured":"Schafer, C. et al. The serum protein alpha 2-Heremans-Schmid glycoprotein\/fetuin-A is a systemically acting inhibitor of ectopic calcification. J. Clin. Invest. 112, 357\u2013366. https:\/\/doi.org\/10.1172\/jci17202 (2003).","journal-title":"J. Clin. Invest."},{"key":"55364_CR45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/s0140-6736(03)12710-9","volume":"361","author":"M Ketteler","year":"2003","unstructured":"Ketteler, M. et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: A cross-sectional study. Lancet 361, 827\u2013833. https:\/\/doi.org\/10.1016\/s0140-6736(03)12710-9 (2003).","journal-title":"Lancet"},{"key":"55364_CR46","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1093\/ndt\/gfh891","volume":"20","author":"AY Wang","year":"2005","unstructured":"Wang, A. Y. et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol. Dial. Transplant. 20, 1676\u20131685. https:\/\/doi.org\/10.1093\/ndt\/gfh891 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"55364_CR47","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2022.02.021","volume":"355","author":"M Alkalbani","year":"2022","unstructured":"Alkalbani, M., Prabhu, G., Lagbo, J. & Qayyum, R. Serum Klotho and pulse pressure; Insight from NHANES. Int. J. Cardiol. 355, 54\u201358. https:\/\/doi.org\/10.1016\/j.ijcard.2022.02.021 (2022).","journal-title":"Int. J. Cardiol."},{"key":"55364_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-79139-8","volume":"11","author":"W-Y Liang","year":"2021","unstructured":"Liang, W.-Y. et al. No significant association of serum klotho concentration with blood pressure and pulse wave velocity in a Chinese population. Sci. Rep. 11, 1\u20138 (2021).","journal-title":"Sci. Rep."},{"key":"55364_CR49","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12882-018-0851-3","volume":"19","author":"HJ Kim","year":"2018","unstructured":"Kim, H. J. et al. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: Results from the KNOW-CKD study. BMC Nephrol. 19, 51. https:\/\/doi.org\/10.1186\/s12882-018-0851-3 (2018).","journal-title":"BMC Nephrol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55364-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55364-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T11:04:29Z","timestamp":1708772669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-55364-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["55364"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-55364-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3089809\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"21 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4554"}}